Health and Fitness Health and Fitness
Tue, February 3, 2009
[ 01:00 PM ] - Market Wire
Cytokinetics, Inc.: Cytokinetics to Announce Four .. Quarter and Year End Results on February 10, 2009
[ 12:48 PM ] - Market Wire
CardioNet, Inc. to Release Fourth Quarter and Full Year 2008 Earnings Results on February 17, 2009
[ 12:10 PM ] - Market Wire
Trimeris Reports Fourth Quarter 2008 FUZEON® Sales Results
[ 12:05 PM ] - Market Wire
Ligand to Present at BIO CEO and Investor Conference on February 9
[ 12:01 PM ] - Market Wire
CombinatoRx to Present at 11th Annual BIO CEO & Investor Conference
[ 09:28 AM ] - Market Wire
Genzyme Center Wins Prestigious Architecture Award
[ 09:24 AM ] - Market Wire
MedaSorb Technologies Corporation: MedaSorb Technologies Corporation Improves Balance Sheet
[ 09:16 AM ] - Market Wire
NexMed to Present at the 11th Annual BIO CEO & Investor Conference
[ 08:58 AM ] - Market Wire
Schaeffer's Sentiment Snapshot: Kinetic Concepts, Inc. (KCI)
[ 08:06 AM ] - Market Wire
Molecular Insight Pharmaceuticals, Inc. : Molecul .. Inc. to Present at BIO CEO & Investor Conference
[ 07:33 AM ] - Market Wire
Humana Inc. to Present at 2009 UBS Global Health Service Conference
[ 07:25 AM ] - Market Wire
Remedent, Inc. to Present at the Roth Capital Partners 21st Annual OC Growth Stock Conference
[ 07:18 AM ] - Market Wire
Universal American Corp. Schedules Fourth Quarter .. or Tuesday, February 17th and Conference Call for
[ 06:47 AM ] - Market Wire
HemoBioTech Announces Addition of R. E. Corky Dragoo, Jr. to Board of Directors
[ 06:30 AM ] - Market Wire
Community Health Systems to Participate in the 2009 UBS Global Healthcare Services Conference
[ 06:25 AM ] - Market Wire
MDRNA, Inc.: MDRNA, Inc. Announces Receipt of Mil .. Agreement With Amylin Pharmaceuticals, Inc. for D
[ 05:55 AM ] - Market Wire
IntegraMed to Host Q4 Conference Call Tuesday, February 17th at 10:00 a.m. EST
[ 05:36 AM ] - Market Wire
Curis to Release Fourth Quarter and Year-end 2008 .. lts and Hold Conference Call on February 10, 2009
[ 05:30 AM ] - Market Wire
NexMed Announces Sale of U.S. Rights for Topical Erectile Dysfunction Treatment
[ 05:15 AM ] - Market Wire
GenVec to Present at the 11th Annual BIO CEO & Investor Conference
[ 05:00 AM ] - Market Wire
ACADIA Pharmaceuticals to Present at the BIO CEO & Investor Conference on February 10, 2009
[ 05:00 AM ] - Market Wire
PhytoMedical?s Patented Anti-Cancer Compound Erad .. ccessful In-Vivo Tests against Human Brain Cancer
[ 05:00 AM ] - Market Wire
Webcast of QIAGEN N.V.'s (Nasdaq: QGEN) Fourth Qu .. d 2008 Financial Results Call Set for February 10
[ 04:30 AM ] - Market Wire
Response Genetics Signs Agreement With Roche Diagnostics to Support Cancer Test Development
[ 04:30 AM ] - Market Wire
Depomed to Present at Upcoming Conferences
[ 04:30 AM ] - Market Wire
BioReference Laboratories, Inc to Speak at The UBS Global Healthcare Services Conference
[ 04:30 AM ] - Market Wire
Fonar Corporation: FONAR Granted Additional NASDAQ Extension
[ 04:00 AM ] - Market Wire
PerkinElmer Expands LED Portfolio with Acquisition of Opto Technology, Inc.
[ 04:00 AM ] - Market Wire
King Pharmaceuticals Announces Corporate Restructuring to Reduce Operating Expenses
[ 04:00 AM ] - Market Wire
Affymax to Present at BIO CEO and Investor Conference

Affymax to Present at BIO CEO and Investor Conference


Published on 2009-02-03 05:38:38, Last Modified on 2009-02-03 05:39:00 - Market Wire
  Print publication without navigation


PALO ALTO, Calif.--([ BUSINESS WIRE ])--Affymax, Inc. (Nasdaq:AFFY) today announced that Arlene Morris, president and chief executive officer, will present at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10, 2009, at 2:15 p.m. ET at the Waldorf Astoria in New York City.

A live webcast of the presentation will be available on the investors section of the Company's website at [ www.affymax.com ]. A replay will also be available for 30 days following the presentation.

About Affymax, Inc.

Affymax, Inc. is a biopharmaceutical company developing novel drugs to improve the treatment of serious and often life-threatening conditions. Affymax's product candidate, Hematide™, is currently in Phase 3 clinical trials for the treatment of anemia associated with chronic renal failure. For additional information, please visit [ www.affymax.com ].

Contributing Sources